 |
      |
|
|
|
|
|
|
|
 |
 |
 |
 |
|||
|
Have you screened your patients for coexisting systemic conditions and medications? Many glaucoma patients have additional medical conditions.
It's important to ask your patients about their other medical conditions,
as well as what prescriptions they take. This will allow you to determine
which patients have coexisting systemic conditions so you can choose
a glaucoma treatment that won't interfere with their medications or
adversely affect their Has your patient been diagnosed with any of the following? Cardiovascular disorders, such as arteriosclerosis, congestive heart failure, coronary artery disease, pulmonary disease, or hypertension
Metabolic disorders, such as diabetes
Lung disorders, such as asthma or COPD
Other disorders, including sexual dysfunction or anxiety/depression
It's also important to discuss your patient's family medical history, as many conditions are hereditary. The more information you have, the better the treatment you can offer Communication is key! Please contact your Allergan Sales Representative for corresponding patient |
 |
|
Indication: ALPHAGAN® P 0.1% ophthalmic solution is indicated for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or Important Safety Information Contraindication: ALPHAGAN® P 0.1% is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. Precautions: Although ALPHAGAN® P 0.1% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. ALPHAGAN® P 0.1% should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or Adverse reactions: Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and Please click here for full prescribing information. |
|
